1. 905PDMultiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC). (1st October 2019) Authors: Necchi, A; Madison, R; Chung, J; Raggi, D; Briganti, A; Montorsi, F; Boormans, J L; Liu, Y; De Jong, J J; Chung, J; Black, P C; Ross, J S; Ali, S M; Davicioni, E; Gibb, E A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. (19th November 2019) Authors: Horwich, A; Babjuk, M; Bellmunt, J; Bruins, H M; Reijke, T M De; Santis, M De; Gillessen, S; James, N; Maclennan, S; Palou, J; Powles, T; Ribal, M J; Shariat, S F; Kwast, T Van Der; Xylinas, E; Agarwal, N; Arends, T; Bamias, A; Birtle, A; Black, P C Journal: Annals of oncology Issue: Volume 30:Number 11(2019) Page Start: 1697 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗